Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 Administered Via an Intraperitoneal Route in Patients With High Grade Serous or Endometrioid Ovarian Cancer

Next Previous
Trial Profile

A Phase I, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 Administered Via an Intraperitoneal Route in Patients With High Grade Serous or Endometrioid Ovarian Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs THEO 260 (Primary) ; THEO 260 (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer
  • Focus Adverse reactions
  • Acronyms OCTOPOD-IP
  • Sponsors Theolytics

Most Recent Events

  • 28 May 2026 According to Theolytics media release, this phase I trial presented as a 'Trials in Progress' poster at the 2026 American Society for Clinical Oncology (ASCO) World Congress. ASCO is taking place in Chicago, US from May 29 - June 2.
  • 28 Apr 2026 According to Theolytics media release, the first patient has been dosed in this trial.
  • 22 Apr 2026 Planned End Date changed from 1 Dec 2027 to 1 Sep 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top